TriangleCIML NK cells for AML (NCT06152809)
CIML NK cells for AML trial for Acute Myeloid Leukemia (NCT06152809). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for acute myeloid leukemia in which a small amount of disease remains after treatment, called measurable residual disease.
The idea: combine two treatments. Natural killer cells from a donor are trained in the lab with cytokines to become memory-like, and infused after lymphodepleting chemotherapy, with interleukin-2 injections. Venetoclax, a pill approved for this leukemia that blocks a protein called BCL-2, is taken alongside.
This is the first time the combination will be given to people. About 10 participants will be treated, with a hospital stay of up to four weeks. At Dana-Farber in Boston, Evan Chen leads this safety study.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.